Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure BioSciences unveils Barocycler 2320EXT at international conference

Pressure BioSciences, Inc. has unveiled its latest addition to its product line based on a patented and powerful pressure cycling technology platform, the Barocycler 2320EXTREME
Pressure BioSciences unveils Barocycler 2320EXT at international conference
Pressure BioSciences Barocycler 2320EXT unveiled

Pressure BioSciences, Inc. (OTCMKTS:PBIO) on Wednesday unveiled its latest addition to its product line based on a patented and powerful pressure cycling technology ("PCT") platform, the Barocycler 2320EXTREME ("2320EXT").

The product unveiling took place during the recent annual conference of the American Society for Mass Spectrometry ("ASMS") in San Antonio, Texas. 

Pressure BioSciences also announced that scientists from six separate research groups made presentations on the company's PCT-based product line at the same international conference.

Results presented indicated that the company's PCT-based instruments and consumables, when used in the preparation of samples for mass spectrometric analysis, resulted in critically enabling qualitative and quantitative improvements and/or improved time or cost efficiency.

Presentations were made by scientists from the Children's Medical Research Institute (Sydney, Australia), the Johns Hopkins University School of Medicine, the Center for Food Safety and Applied Nutrition - Food and Drug Administration (FDA/CFSAN), Northwestern University, and Pressure BioSciences together with Protifi LLC.

The ASMS Conference is one of the largest annual meetings of mass spectrometry professionals worldwide.  The Company took advantage of this opportunity to unveil the Barocycler 2320EXTREME. This addition to PBI's product line was designed with a number of new and enhanced features and benefits that should enable scientists better access to the biomolecules (e.g., proteins, lipids, nucleic acids) in samples being studied, with the potential to result in new biological insights and discoveries, and rapid growth for PBI.  The Barocycler 2320EXT is expected to become the centerpiece of the recently announced co-marketing agreement with global life sciences analytical technologies leader SCIEX.

"Our participation in the recent ASMS Conference greatly exceeded our expectations, both in relation to the unveiling of the new Barocycler 2320EXT, and to the number and content of presentations by well-respected scientific groups on the advantages/benefits of our PCT-based product line when used in the critical area of sample preparation," said Dr. Nate Lawrence, Vice President of Marketing and Sales.

"We had nearly 1,000 attendees visit our exhibition booth and hospitality suite.  A number of these visitors were genuinely interested in learning about the advantages of PCT, and the features and benefits of the new Barocycler 2320EXT.  We are actively following up with these contacts, and expect that some of these scientists/groups will become PBI customers in the near future," he added.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

1527682514_angel-delight.jpg
May 30 2018
The latest fundraiser underscores the fact the life sciences business is well supported in the City
1528305384_Untitled-design-(3).jpg
June 07 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
Workers at CERN
August 02 2018
Private banks and healthcare groups took part in the share placing

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use